Integer Holdings Corporation posted an 11% increase in revenue, reaching $449 million in Q4 2024. GAAP operating income grew by 31% to $57 million, while net income rose 23% to $33 million. Adjusted EPS increased slightly to $1.43 per share. The company expects 8-10% sales growth in 2025 with improving margins.
Integer Holdings Corporation announced its Third Quarter 2024 results, showcasing a 10% sales growth and a 23% increase in adjusted operating income year to date. The company is raising the midpoint of its full year adjusted operating income outlook by $4 million. The divestiture of Electrochem is expected to close later this month, transforming Integer into a pure-play medical technology company.
Integer Holdings Corporation announced strong second-quarter results, featuring 9% sales growth and a 20% increase in adjusted operating income. The company raised its full-year adjusted operating income growth outlook to 14% to 21%, reflecting successful execution of its strategy.
Integer Holdings Corporation reported a strong start to 2024, with first quarter sales growing 10% year-over-year and adjusted operating income growing 26%. The company reiterated its 2024 financial outlook, expecting continued sales and adjusted operating income growth.
Integer delivered strong fourth quarter and full year 2023 sales and income, with full year sales up 16% and adjusted operating income growth of 26%. The company expects 9% to 11% sales growth in 2024 and adjusted operating income to grow 13% to 20%. Integer also completed the acquisition of Pulse Technologies in January 2024.
Integer Holdings Corporation reported a strong third quarter with organic sales up 18% and adjusted operating income growth of 39%. The company is increasing its full year sales outlook to 15% growth and adjusted operating income outlook to 25% growth at the midpoint. They also acquired InNeuroCo to strengthen neurovascular catheter capabilities.
Integer Holdings Corporation reported strong second quarter results with increased sales and profit growth. The company is increasing its full year sales outlook to 12% growth and adjusted operating income outlook to 19% growth.
Integer Holdings Corporation reported a strong first quarter in 2023, with sales growing 22% year-over-year, driven by strong demand across all product lines and the recovery of second-half 2022 supplier delays. The company also delivered 28% year-over-year adjusted operating income growth.
Integer Holdings Corporation reported strong sales growth of 19% in Q4 2022. The company expects 7% to 9% organic sales growth in 2023 and adjusted operating income to grow 10% to 16%.
Integer Holdings Corporation reported third quarter 2022 results, with sales and profit results in line with preliminary expectations. The company is intensifying supply chain management to meet strong customer demand and expects above-market revenue growth of 7% to 9% in 2023 with margin expansion.
Integer Holdings Corporation reported second quarter 2022 financial results with sales growing 13% versus the first quarter 2022 and 12% versus prior year. They have raised their full year 2022 sales outlook and expect to grow 12% to 14% versus 2021.
Integer Holdings Corporation reported first quarter 2022 financial results consistent with expectations, with double-digit sales growth expected for the rest of the year, beginning in the second quarter, as well as gross margin improvement through the remainder of 2022. The 2022 outlook now includes the acquisitions of Oscor and Aran Biomedical, with projected sales growth of 11 to 13% and adjusted EBITDA growth of 12 to 17%, year-over-year.
Integer delivered strong year-over-year financial results in the fourth quarter and full year 2021 despite a challenging labor and supply chain environment. The company completed the acquisition of Oscor Inc. and generated $157 million cash flow from operations in the full year.
Integer Holdings Corporation reported strong third-quarter results with year-over-year growth and announced the acquisition of Oscor, Inc. The company also increased its 2021 outlook and completed a debt refinancing expected to increase EPS by $0.15 on an annualized basis.
Integer Holdings Corporation reported strong second-quarter results, demonstrating resilience amidst U.S. labor constraints and global supply chain disruptions. The company increased its full-year 2021 financial outlook, projecting year-over-year sales growth of 12% to 14% and increased free cash flow outlook to generate $95 million to $115 million.
Integer Holdings Corporation reported strong first quarter results, with both sales and profit improving significantly versus the fourth quarter of 2020. The company increased its full year 2021 financial outlook, projecting year-over-year sales growth of 10% to 12% and free cash flow of $90 million to $110 million.
Integer Holdings Corporation reported Q4 2020 results with sales at the high end of guidance and profit above guidance. Strong cash management led to a $123 million reduction in net total debt in 2020.
Integer Holdings Corporation reported third quarter results with improved profitability versus the second quarter. The company expects the fourth quarter to be even stronger, as sales begin to recover from the pandemic and the profit margin rate recovery accelerates.
Integer Holdings Corporation announced results for the three months ended July 3, 2020. The company is managing through the 'new normal' of COVID-19 and continuing to execute its strategy. The company's financial strength, ample liquidity and improved bank covenant cushion, positions it to continue making strategic investments.
Integer Holdings Corporation announced strong first quarter results, largely unaffected by COVID-19, but suspended 2020 guidance due to uncertainty and executed a revolver draw down to protect against a prolonged pandemic.
Integer Holdings Corporation reported strong earnings growth in 2019, driven by the Manufacturing Excellence strategic imperative. The company exceeded its original 2019 adjusted profit guidance and strengthened its leadership team. A bolt-on acquisition was completed, enhancing R&D capabilities and expanding the global footprint into Israel.